{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":26,"n_cols":5,"rows_kept":26,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[3,2,3,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[13,2,13,3],[14,2,14,3],[18,2,18,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910789877703321"]
[null,null,"Titolo",null,"Pharmacoepidemiology [[electronic resource] /] / edited by Brian L. Strom, Stephen E. Kimmel, Sean Hennessy"]
[null,null,"Pubbl/distr/stampa",null,"Chichester, West Sussex, UK, : Wiley-Blackwell, 2012"]
[null,null,"ISBN",null,"1-280-59892-1"]
[{"$nulls":4},"9786613628756"]
[{"$nulls":4},"1-119-95994-2"]
[{"$nulls":4},"1-119-95991-8"]
[{"$nulls":4},"1-119-95992-6"]
[null,null,"Edizione",null,"[5th ed.]"]
[null,null,"Descrizione fisica",null,"1 online resource (977 p.)"]
[null,null,"Disciplina",null,"615/.7042"]
[null,null,"Soggetti",null,"Pharmacoepidemiology"]
[{"$nulls":4},"Pharmacology"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Pharmacoepidemiology, FIFTH EDITION; Contents; List of Contributors; Preface; Acknowledgements; PART I: Introduction; CHAPTER 1: What is Pharmacoepidemiology?; CHAPTER 2: Basic Principles of Clinical Pharmacology Relevant to Pharmacoepidemiologic Studies; CHAPTER 3: Basic Principles of Clinical Epidemiology Relevant to Pharmacoepidemiologic Studies; CHAPTER 4: Sample Size Considerations for Pharmacoepidemiologic Studies; CHAPTER 5: When Should One Perform Pharmacoepidemiologic Studies?; PART I I: The Role of Pharmacoepidemiology in Different Sectors"]
[{"$nulls":4},"CHAPTER 6: The Role of Pharmacoepidemiology in the Health-Care System and AcademiaCHAPTER 7: The Role of Pharmacoepidemiology in Industry; CHAPTER 8: The Role of Pharmacoepidemiology in Regulatory Agencies; CHAPTER 9: Pharmacoepidemiology and the Law; PART I I I: Sources of Data for Pharmacoepidemiologic Studies; Section A: Spontaneous Reporting; CHAPTER 10: Postmarketing Spontaneous Pharmacovigilance Reporting Systems; Section B: Automated Data Systems; CHAPTER 11: Overview of Automated Databases in Pharmacoepidemiology; CHAPTER 12: Health Maintenance Organizations/Health Plans"]
[{"$nulls":4},"CHAPTER 13: Commercial Insurance DatabasesCHAPTER 14: US Government Claims Databases; CHAPTER 15: Medical Record "]
[{"$nulls":4},"Databases; CHAPTER 16: In-hospital Databases; CHAPTER 17: Canadian Provincial Databases; CHAPTER 18: Pharmacy-based Medical Record Linkage Systems; Section C: Ad Hoc Studies-Ongoing Systems for Pharmacoepidemiologic Studies; CHAPTER 19: Case-Control Surveillance; CHAPTER 20: Prescription-Event Monitoring; CHAPTER 21: Registries; Section D: Ad Hoc Studies-De Novo Studies; CHAPTER 22: Field Studies; Section E: Choosing Among the Available Alternatives"]
[{"$nulls":4},"CHAPTER 23: How Should One Perform Pharmacoepidemiologic Studies? Choosing Among the Available AlternativesPART IV: Selected Special Applications of Pharmacoepidemiology; CHAPTER 24: Studies of Drug Utilization; CHAPTER 25: Evaluating and Improving Physician Prescribing; CHAPTER 26: Pharmacoepidemiologic Studies of Vaccine Safety; CHAPTER 27: Epidemiologic Studies of Medical Devices: Methodologic Considerations for Implantable Devices; CHAPTER 28: Studies of Drug-Induced Birth Defects; CHAPTER 29: Risk Management"]
[{"$nulls":4},"CHAPTER 30: FDA's Sentinel Initiative: Active Surveillance to Identify Safety SignalsCHAPTER 31: Pharmacoepidemiology and Pharmaceutical Reimbursement Policy; CHAPTER 32: Comparative Effectiveness Research; PART V: Selected Special Methodologic Issues in Pharmacoepidemiology; CHAPTER 33: Assessing Causality of Case Reports of Suspected Adverse Events; CHAPTER 34: Molecular Pharmacoepidemiology; CHAPTER 35: Bioethical Issues in Pharmacoepidemiologic Research; CHAPTER 36: The Use of Randomized Controlled Trials for Pharmacoepidemiologic Studies"]
[{"$nulls":4},"CHAPTER 37: The Use of Pharmacoepidemiology to Study Beneficial Drug Effects"]
[null,null,null,"Sommario/riassunto","Now in its fifth edition, Pharmacoepidemiology defines the discipline and provides the most comprehensive guidance of any book on the topic. Written by world renowned experts in the field, this valuable text surveys the research designs and sources of data available for pharmacoepidemiologic research, and provides descriptions of various automated data systems, along with the advantages and disadvantages of each.  Incorporating perspectives from academia, industry and regulatory agencies, this book provides detailed insights into all aspects of pharmacoepidemiology."]